Risk stratification for indolent lymphomas
Autor(a) principal: | |
---|---|
Data de Publicação: | 2010 |
Outros Autores: | , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Revista brasileira de hematologia e hemoterapia (Online) |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842010000500015 |
Resumo: | Indolent B-cell lymphomas account for approximately 40% of all non-Hodgkin lymphomas (NHLs). Advances in technology have contributed to improvements in the diagnosis and classification of indolent non-Hodgkin lymphomas. Follicular Lymphomas are the most common although the frequency varies significantly throughout the world. The description of the Follicular Lymphoma International Prognostic Index (FLIPI) was an important step in identifying patient subgroups, but its use in the clinical practice has not been established yet. The use of a larger number of paraffin active monoclonal antibodies for immunohistochemistry, molecular cytogenetic studies including standard cytogenetics, multi-color fluorescence in-situ hybridization (FISH), polymerase chain reaction and locus-specific fluorescence insitu hybridization as well as developments in high-resolution techniquesincluding microarray gene expression profiling allow more accurate diagnosis andprecise definition of biomarkers of value in risk stratification. The identification ofdiseasespecific gene lists resulting from expression profiling provides a number ofpotential protein targets that can be validated using immunohistochemistry. Analysesof gene expression profiles or constitutive gene variations may also provide additional insight for prognostication in the near future. A comprehensive understanding of the biology of these distinct lymphoid tumors will allow us to identify novel diseaserelated genes and should facilitate the development of improved diagnosis, outcome prediction, and personalized approaches to treatment. |
id |
ABHHTC-1_10d35c300a946868c9b8e29c4eeda2ee |
---|---|
oai_identifier_str |
oai:scielo:S1516-84842010000500015 |
network_acronym_str |
ABHHTC-1 |
network_name_str |
Revista brasileira de hematologia e hemoterapia (Online) |
repository_id_str |
|
spelling |
Risk stratification for indolent lymphomasLymphoma, non-HodgkinPrognosisTreatment outcomeBiologic markersLymphoma, B-cellLymphoma, follicular/pathologyIndolent B-cell lymphomas account for approximately 40% of all non-Hodgkin lymphomas (NHLs). Advances in technology have contributed to improvements in the diagnosis and classification of indolent non-Hodgkin lymphomas. Follicular Lymphomas are the most common although the frequency varies significantly throughout the world. The description of the Follicular Lymphoma International Prognostic Index (FLIPI) was an important step in identifying patient subgroups, but its use in the clinical practice has not been established yet. The use of a larger number of paraffin active monoclonal antibodies for immunohistochemistry, molecular cytogenetic studies including standard cytogenetics, multi-color fluorescence in-situ hybridization (FISH), polymerase chain reaction and locus-specific fluorescence insitu hybridization as well as developments in high-resolution techniquesincluding microarray gene expression profiling allow more accurate diagnosis andprecise definition of biomarkers of value in risk stratification. The identification ofdiseasespecific gene lists resulting from expression profiling provides a number ofpotential protein targets that can be validated using immunohistochemistry. Analysesof gene expression profiles or constitutive gene variations may also provide additional insight for prognostication in the near future. A comprehensive understanding of the biology of these distinct lymphoid tumors will allow us to identify novel diseaserelated genes and should facilitate the development of improved diagnosis, outcome prediction, and personalized approaches to treatment.Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular2010-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842010000500015Revista Brasileira de Hematologia e Hemoterapia v.32 n.5 2010reponame:Revista brasileira de hematologia e hemoterapia (Online)instname:Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)instacron:ABHHTC10.1590/S1516-84842010000500015info:eu-repo/semantics/openAccessHallack Neto,Abrahão EliasCosta,Renata OliveiraAtalla,AngeloDulley,Frederico LuizChamone,Dalton Alencar FischerPereira,Julianaeng2012-02-01T00:00:00Zoai:scielo:S1516-84842010000500015Revistahttp://www.rbhh.org/pt/archivo/https://old.scielo.br/oai/scielo-oai.phpsbhh@terra.com.br||secretaria@rbhh.org1806-08701516-8484opendoar:2012-02-01T00:00Revista brasileira de hematologia e hemoterapia (Online) - Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)false |
dc.title.none.fl_str_mv |
Risk stratification for indolent lymphomas |
title |
Risk stratification for indolent lymphomas |
spellingShingle |
Risk stratification for indolent lymphomas Hallack Neto,Abrahão Elias Lymphoma, non-Hodgkin Prognosis Treatment outcome Biologic markers Lymphoma, B-cell Lymphoma, follicular/pathology |
title_short |
Risk stratification for indolent lymphomas |
title_full |
Risk stratification for indolent lymphomas |
title_fullStr |
Risk stratification for indolent lymphomas |
title_full_unstemmed |
Risk stratification for indolent lymphomas |
title_sort |
Risk stratification for indolent lymphomas |
author |
Hallack Neto,Abrahão Elias |
author_facet |
Hallack Neto,Abrahão Elias Costa,Renata Oliveira Atalla,Angelo Dulley,Frederico Luiz Chamone,Dalton Alencar Fischer Pereira,Juliana |
author_role |
author |
author2 |
Costa,Renata Oliveira Atalla,Angelo Dulley,Frederico Luiz Chamone,Dalton Alencar Fischer Pereira,Juliana |
author2_role |
author author author author author |
dc.contributor.author.fl_str_mv |
Hallack Neto,Abrahão Elias Costa,Renata Oliveira Atalla,Angelo Dulley,Frederico Luiz Chamone,Dalton Alencar Fischer Pereira,Juliana |
dc.subject.por.fl_str_mv |
Lymphoma, non-Hodgkin Prognosis Treatment outcome Biologic markers Lymphoma, B-cell Lymphoma, follicular/pathology |
topic |
Lymphoma, non-Hodgkin Prognosis Treatment outcome Biologic markers Lymphoma, B-cell Lymphoma, follicular/pathology |
description |
Indolent B-cell lymphomas account for approximately 40% of all non-Hodgkin lymphomas (NHLs). Advances in technology have contributed to improvements in the diagnosis and classification of indolent non-Hodgkin lymphomas. Follicular Lymphomas are the most common although the frequency varies significantly throughout the world. The description of the Follicular Lymphoma International Prognostic Index (FLIPI) was an important step in identifying patient subgroups, but its use in the clinical practice has not been established yet. The use of a larger number of paraffin active monoclonal antibodies for immunohistochemistry, molecular cytogenetic studies including standard cytogenetics, multi-color fluorescence in-situ hybridization (FISH), polymerase chain reaction and locus-specific fluorescence insitu hybridization as well as developments in high-resolution techniquesincluding microarray gene expression profiling allow more accurate diagnosis andprecise definition of biomarkers of value in risk stratification. The identification ofdiseasespecific gene lists resulting from expression profiling provides a number ofpotential protein targets that can be validated using immunohistochemistry. Analysesof gene expression profiles or constitutive gene variations may also provide additional insight for prognostication in the near future. A comprehensive understanding of the biology of these distinct lymphoid tumors will allow us to identify novel diseaserelated genes and should facilitate the development of improved diagnosis, outcome prediction, and personalized approaches to treatment. |
publishDate |
2010 |
dc.date.none.fl_str_mv |
2010-01-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842010000500015 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842010000500015 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1590/S1516-84842010000500015 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular |
publisher.none.fl_str_mv |
Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular |
dc.source.none.fl_str_mv |
Revista Brasileira de Hematologia e Hemoterapia v.32 n.5 2010 reponame:Revista brasileira de hematologia e hemoterapia (Online) instname:Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC) instacron:ABHHTC |
instname_str |
Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC) |
instacron_str |
ABHHTC |
institution |
ABHHTC |
reponame_str |
Revista brasileira de hematologia e hemoterapia (Online) |
collection |
Revista brasileira de hematologia e hemoterapia (Online) |
repository.name.fl_str_mv |
Revista brasileira de hematologia e hemoterapia (Online) - Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC) |
repository.mail.fl_str_mv |
sbhh@terra.com.br||secretaria@rbhh.org |
_version_ |
1754213110339600384 |